Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin for Radiation-Induced Pain in Head and Neck Cancer
NCT03747562Phase 3Withdrawn
- Sponsor
- Ghent University Hospital
- Start
- Mar 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gabapentin in pain and neuropathic pain (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Requirement of patients included in 7-week curative radio(chemo)therapy for a (dose-escalation of) strong opioid. Planned start Mar 2019; status: withdrawn.
02
Drugs
gabapentin
03
Conditions
painneuropathic pain
Beyond the preview
Go deeper on NCT03747562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747562.